STATISTICAL INTERPRETATION AND OPTIMIZATION OF VALSARTAN FLOATING TABLETS USING BOX-BEHNKEN DESIGN
Keywords:Valsartan, Floating drug delivery system, Box-Bentham design, Akaike Information Criterion (AIC), Mean dissolution time
Objective: The main purpose of this study was to formulate and statistically evaluate 300 mg floating tablets of valsartan.
Methods: Floating tablets of valsartan was prepared in 16 station rotary punching machine by considering 300 mg of valsartan as drug, 40-60 mg of hydroxypropyl methylcellulose (HPMC) K100M and 20-40 mg of poly (styrene-divinylbenzene) as polymers and 20 mg of sodium bicarbonate as gas generating agents. Since upper stomach has maximum therapeutic window for valsartan absorption, hence Gastroretentive Floating Tablets (GRFTs) was prepared by implementing Box-Bentham Design. The pre and post compression parameters were optimized using Statistica 10 software. From the in vitro buoyancy and drug release studies and interpretation of statistical outcomes viz. Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), Root Mean Squared Error (RMSE), Dissolution Efficiency (DE), Mean Dissolution Time (MDT), desirability study, it was concluded that batch VF5 formulation was found to be the most optimized formulation.
Results: The floating time of VF5 was found to be 132±0.33 sec, in vitro buoyancy time was 18 h, Akaike Information Criterion (AIC) was 54.97, Bayesian Information Criterion (BIC) was 5.13, percentage dissolution efficacy was 56.39%, mean dissolution time was 5.19hr. Further, six-month stability study was performed as per ICH QIA guideline. After performing two-way ANOVA within stability study response variables, it was confirmed that the interaction was most significant.
Conclusion: Valsartan floating drug delivery system was successfully developed by considering HPMC K100M and poly (styrene-divinylbenzene) as polymers. Among all the nine batches, VF5 was found to be the best-optimized batch.
Iborra Egea O, Galvez Monton C, Roura S, Perea Gil I, Prat Vidal C, Soler Botija C, et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. NPJ Syst Biol Appl 2017;3:12.
Ansara AJ, Kolanczyk DM, Koehler JM. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. J Clin Pharm Ther 2016;41:119-27.
Verdecchia P, Angeli F. Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin Thera 2004;26:460-72.
Kshirsagar SJ, Patil SV, Bhalekar MR. Statistical optimization of floating pulsatile drug delivery system for chronotherapy of hypertension. Int J Pharm Invest 2011;1:207-13.
Sokar M, Hanafy A, Elkamel A, El-Gamal S. Design of chronomodulated drug delivery system of valsartan: in vitro characterization. Indian J Pharm Sci 2015;77:470-7.
Mandal UK, Chatterjee B, Senjoti FG. Gastro-retentive drug delivery systems and their in vivo success: a recent update. Asian J Pharm Sci 2016;11:575-84.
Marini A, Berbenni V, Moioli S, Bruni G, Cofrancesco P, Margheritis C, et al. Drug-excipient compatibility studies by Physico-chemical techniques: the case of Indomethacin. J Therm Anal Calorim 2003;73:529-45.
Vemula S, Venisetty RK, Veerareddy P. Valsartan floating bioadhesive compression-coated mini-tablets: formulation and pharmacokinetics; 2017.
Ahmed MS, Afaf AR, Amal SmAE-e, Yasmin IMM. Formulation and optimization of itraconazole proteasomes using box behnken design. Int J Appl Pharm 2018;10:41.
Anas TA, Ali Khidher A. Formulation and in vitro evaluation of amlodipine gastro retentive floating tablets using a combination of hydrophilic and hydrophobic polymers. Int J Appl Pharm 2018;10:126-34.
Gharti KP, Thapa P, Budhathoki U, Bhargava A. Formulation and in vitro evaluation of floating tablets of hydroxypropyl methylcellulose and polyethylene oxide using ranitidine hydrochloride as a model drug. J Young Pharm JYP 2012;4:201-8.
Senjoti FG, Mahmood S, Jaffri JM, Mandal UK. Design and in vitro evaluation of sustained-release floating tablets of metformin HCl based on effervescence and swelling. Iranian J Pharm Res 2016;15:53-70.
Malana MA, Zohra R. The release behavior and kinetic evaluation of tramadol HCl from chemically cross-linked ter polymeric hydrogels. DARU J Pharm Sci 2013;21:10.
Brewer MJ, Butler A, Cooksley SL. The relative performance of AIC, AICC and BIC in the presence of unobserved heterogeneity. Methods Ecol Evolution 2016;7:679-92.
Bose A, Wong TW, Singh N. Formulation development and optimization of sustained release matrix tablet of Itopride HCl by response surface methodology and its evaluation of release kinetics. Saudi Pharm J 2013;21:201-13.